Since 2007, FRG®KO mice have been used in gene and cell therapy applications to improve translatability between conventional mouse studies and the development of human therapeutics.
While gene editing technologies have evolved rapidly over the last decade, drug developers are struggling to advance programs to market. Designing gene delivery vehicles using traditional rodent models translates poorly to the clinic because these models lack human relevance.
Liver-humanized FRG mice provide a critical toolset for researchers in this space by allowing optimization, verification of target specificity, and evaluation of off-target effects in a human-relevant setting. When speed and accuracy are critical to your program’s success, Yecuris in vitro and in vivo technologies are there to bridge the gap between bench and clinic.
In addition to their utility as models for testing genome editing therapy delivery systems, liver humanized mice have unique qualities that make them suitable for use in screening the metabolic activities of new drugs and toxicology, for hepatotropic infectious diseases, and for studies of genetic and metabolic liver diseases.
Research Services at Yecuris: The collaborative difference.
Running your study with us gives you access to:
- Deep expertise in working with humanized animal models
- Specialized facility to house & maintain immunodeficient animals
- Skilled staff with the experience to manage your study from design to results
Welcome to the Gene Therapy Club!
Are FRG liver-humanized mice replacing traditional murine models as the new preclinical standard for liver-focused gene therapies?
The common use of FRG technology to produce results presented in posters and oral presentations at ASGCT 2022 is an indicator of how heavily drug developers are relying on liver-humanized mice for their preclinical in vivo research.
Our scientists specialize in applications related to humanized mice and function as an extension of your lab. We will ensure that your experimental design is consistent with other similar experiment setups that are common within industry and academia. See how FRG mice can speed up your program by joining the Gene Therapy Club. Reach out to our scientists today to get your next study designed and initiated!
Custom Model Generation
FRG mice offer a powerful advantage over other humanized mouse models. The platform can be transplanted with cells from any donor or species to yield an infinite number of phenotypic model variants. We’ve worked with hundreds of clients for over a decade to incorporate normal, super, and mutant donors for drug metabolism, NASH, metabolic disease, and infectious disease. Whether you’re looking to bridge data from previous experiments to a human-relevant model, or looking to create your own novel model, the FRG platform is the ideal solution.
HepaSpecies™ Cross-Species Donor Comparisons Using FRG Mice
Streamline your process. The efficiency of gene therapy vectors can vary widely from one species to the next, making pre-clinical validation difficult and costly. Yecuris offers FRG mice repopulated with hepatocytes from a variety of species, including humans, mice, NHP, and others. These models can accelerate the development of your liver-targeted gene therapy vector in a cost-effective manner.
Running your next HBV experiment in our US-based ABSL-2 vivarium means you can skip complicated logistics and rely on Yecuris as your one-stop shop. The ABSL-2 vivarium is also suitable for AAV selection studies, including replication-competent AAV and AdV.
HepFinity™ Human Hepatocyte Expansion Services
Have you found that hepatocyte donors with genetic variants are becoming more and more difficult to procure? The FRG mice are often used as a bioreactor by taking a single vial of precious hepatocytes and allowing them to repopulate in vivo to generate 5X to 6X more viable hepatocytes.
AAV Integration Analysis in Human Hepatocytes
Yecuris’ AAV integration service is designed to assist rAAV developers in identifying clinical risk as early as possible. Researchers can use the isolated human hepatocytes for downstream sequence analysis to identify rare integration events. Screen and optimize construct design in FRG mice or evaluate your lead construct before going to the clinic.